Produção Nacional
Revisado por pares
Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis
2023; Taylor & Francis; Volume: 16; Issue: 12 Linguagem: Inglês
10.1080/17474086.2023.2293096
ISSN1747-4086
AutoresRoberto Lúcio Muniz, Ricardo Mesquita Camelo, Maiara Silva Araújo, Mariana Michel Barbosa, Augusto Afonso Guerra, Francisco de Assis Acúrcio, Juliana Álvares-Teodoro,
Tópico(s)Hemophilia Treatment and Research
ResumoBackground Emicizumab is a monoclonal antibody approved for prophylaxis against bleeds for people with hemophilia A (PwHA). A systematic review was conducted evaluating the efficacy/effectiveness and the safety of emicizumab as prophylaxis for PwHA compared to prophylaxis with factor VIII (FVIII) or bypassing agents (BPA), respectively in patients without and with inhibitors.
Referência(s)